Vectura Group PLC (VEC.L)
82.75GBp
9:08am BST
-0.30 (-0.36%)
83.05
84.50
84.50
81.70
28,163
1,109,808
90.15
65.85
About
Overall
| Beta: | 0.78 |
| Market Cap(Mil.): | £553.37 |
| Shares Outstanding(Mil.): | 666.30 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VEC.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 32.51 | 37.25 |
| EPS (TTM): | -0.13 | -- | -- |
| ROI: | -14.73 | 12.52 | 12.15 |
| ROE: | -16.44 | 13.83 | 16.99 |
Drugmaker Vectura parts ways with CEO Ward-Lilley
British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.
UPDATE 1-Drugmaker Vectura parts ways with CEO Ward-Lilley
June 10 British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.
Drugmaker Vectura CEO James Ward-Lilley to step down
June 10 British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.
BRIEF-Vectura Group To Receive $2.5 Mln Milestone Payment For QVM149 Submission
* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:
UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S
British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.
UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.
May 4 British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.
Vectura hopes new respiratory device will breathe life into business
Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.
Vectura hopes new respiratory device will breathe life into business
Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.
UPDATE 3-Vectura hopes new respiratory device will breathe life into business
* Forecasts 2018 adjusted core earnings above market forecasts
UK drugmaker Vectura expects 2018 earnings to top market forecasts
Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.
Earnings vs. 
Estimates
- Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?
- Are Vectura Group PLC, AstraZeneca plc And Lookers PLC 'Screaming Buys'?
- Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than GlaxoSmithKline plc?
- Why Vectura Group PLC Could Be The Perfect Partner For AstraZeneca plc In Your Portfolio
- Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC